Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Submits Mozobil In U.S. And Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Stem-cell mobilizer targets a shrinking niche market, analyst tells "The Pink Sheet" DAILY.

You may also be interested in...



FDA Approves Genzyme’s Mozobil For Bone Marrow Transplant Prep

Firm gains FDA approval for Mozobil, though it likely will encounter commercialization road bumps.

FDA Approves Genzyme’s Mozobil For Bone Marrow Transplant Prep

Firm gains FDA approval for Mozobil, though it likely will encounter commercialization road bumps.

Genzyme’s Synvisc-ONE and Myozyme Could Both See Delays After Advisory Committees

A Dec. 9 advisory committee meeting for the osteoarthritis pain management candidate leaves two weeks for FDA turnaround by the product’s action date.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel